IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v22y2025i5p734-d1649689.html
   My bibliography  Save this article

Multilevel Factors Influencing Perceived Barriers to Adjuvant Endocrine Therapy Among Breast Cancer Patients at Medication Onset

Author

Listed:
  • Timothy Cocozza

    (Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA)

  • Rita Smith

    (Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA)

  • Ana Maria Lopez

    (Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA)

  • Shari Rudoler

    (Department of Radiation Oncology, Thomas Jefferson Torresdale Hospital, Philadelphia, PA 19107, USA)

  • Rachel Slamon

    (Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA)

  • Tingting Zhan

    (Department of Pharmacology, Physiology, and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA)

  • Jazmarie L. Vega

    (Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA 19111, USA)

  • Minal Dhamankar

    (Division of Medical Oncology, Einstein Medical Center, Philadelphia, PA 19107, USA)

  • Aruna Padmanabhan

    (Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA 19111, USA)

  • Suzanne M. Miller

    (Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA 19111, USA)

  • Kuang-Yi Wen

    (Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA)

Abstract

Purpose: Adjuvant endocrine therapy (AET) significantly diminishes recurrence and mortality risks in hormone receptor-positive breast cancer (BCa) patients. Nonetheless, suboptimal adherence and premature discontinuation during the initial year of treatment undermine these positive outcomes. This study aims to understand the potential diverse factors associated with perceived barriers to AET compliance at the onset of medication. Methods: We assessed perceived barriers to AET using the ASK-20 instrument for BCa patients initiating AET within 3 months. Our survey also included demographic variables (e.g., musculoskeletal symptoms) and clinical traits (e.g., medication type). Stepwise regression analyses were employed to elucidate the links between multilevel factors and perceived barriers to AET adherence. Results: In our cohort of 272 women, the mean ASK-12 score was 38.2 +/− 9.2 (range 20–100). In the multivariable regression model, greater perceived barriers to adhering to AET were found to be associated with African American ethnicity (Β = 2.47; 0.53–4.21; p < 0.05), lower self-efficacy in medication management (Β = −0.80; −1.03–−0.58; p < 0.001), higher psychological distress (Β = 2.79; 0.61–4.97; p < 0.05), increased reported distress related to musculoskeletal side effects (Β = 0.64; 0.31–0.97; p < 0.001), weight gain symptoms (Β = 0.61; 0.18–1.03; p < 0.05), less family support (Β = −0.38; −0.53–−0.13; p < 0.05), and higher levels of concern pertaining to AET (Β = 0.64; 0.41–0.87; p < 0.001). Conclusions: Modifiable factors are associated with women’s perceived barriers to AET at the onset of treatment. Proactively addressing patient concerns about AET, improving self-regulatory skills for medication management and family support, and enhancing symptom management strategies, along with addressing distress at the onset of treatment, hold promise for mitigating barriers to AET. Furthermore, recognizing the distinctive challenges faced by African American subgroups is crucial, necessitating culturally tailored interventions to reduce potential disparities and ensure equitable access and adherence to AET. Continued research and tailored interventions are important for optimizing outcomes and reducing the impact of modifiable barriers on AET adherence.

Suggested Citation

  • Timothy Cocozza & Rita Smith & Ana Maria Lopez & Shari Rudoler & Rachel Slamon & Tingting Zhan & Jazmarie L. Vega & Minal Dhamankar & Aruna Padmanabhan & Suzanne M. Miller & Kuang-Yi Wen, 2025. "Multilevel Factors Influencing Perceived Barriers to Adjuvant Endocrine Therapy Among Breast Cancer Patients at Medication Onset," IJERPH, MDPI, vol. 22(5), pages 1-11, May.
  • Handle: RePEc:gam:jijerp:v:22:y:2025:i:5:p:734-:d:1649689
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/22/5/734/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/22/5/734/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:22:y:2025:i:5:p:734-:d:1649689. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.